Randomized Phase II Study of Erlotinib Plus Tivantinib Versus Erlotinib Plus Placebo in Previously Treated Non-Small-Cell Lung Cancer
- Author
- SEQUIST, Lecia V1 ; VON PAWEL, Joachim4 ; RAMLAU, Rodryg8 ; ARTHUR, Susan9 ; GORBACHEVSKY, Igor10 ; SCHWARTZ, Brian3 ; SCHILLER, Joan H4 ; GARMEY, Edward G3 ; AKERLEY, Wallace L5 ; BRUGGER, Wolfram4 ; FERRARI, Dora3 ; YINPU CHEN3 ; COSTA, Daniel B2 ; GERBER, David E6 ; ORLOV, Sergey7
[1] Massachusetts General Hospital Cancer Center and Harvard Medical School, United States
[2] Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, United States
[3] ArQule, Woburn, MA, United States
[4] Schwarzwald-Baar Clinic, Academic Teaching Hospital, University of Freiburg, Villingen-Schwenningen, Germany
[5] Huntsman Cancer Institute, Salt Lake City, UT, United States
[6] Harold C. Simmons Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, United States
[7] Pavlov State Medical University, St. Petersburg, Russian Federation
[8] Regional Lung Disease Centre, and Wielkopolskie Centrum Pulmonologii i Torakochirurgii, Poznan University of Medical Sciences, Poznan, Poland
[9] ICON Clinical Research, Dublin, Ireland
[10] Daiichi Sankyo, Edison, NJ, United States - Source
Journal of clinical oncology. 2011, Vol 29, Num 24, pp 3307-3315, 9 p ; ref : 28 ref
- ISSN
- 0732-183X
- Scientific domain
- Medical oncology
- Publisher
- American Society of Clinical Oncology, Alexandria, VA
- Publication country
- United States
- Document type
- Article
- Language
- Russian
- Keyword (fr)
- Anticancéreux Association médicamenteuse Cancer du poumon Cancérologie Carcinome non petite cellule bronchopulmonaire Chimiothérapie Erlotinib Essai clinique phase II Etude comparative Homme Placebo Randomisation Traitement Anti-EGFR Tivantinib Cancer Dérivé de la quinazoline Enzyme Inhibiteur de la tyrosine kinase Inhibiteur enzyme Pathologie de l'appareil respiratoire Pathologie des bronches Pathologie des poumons Protein-tyrosine kinase Transferases Tumeur maligne
- Keyword (en)
- Antineoplastic agent Drug combination Lung cancer Cancerology non-small cell lung carcinoma Chemotherapy Erlotinib Phase II trial Comparative study Human Placebo Randomization Treatment Cancer Quinazoline derivatives Enzyme Tyrosine kinase inhibitor Enzyme inhibitor Respiratory disease Bronchus disease Lung disease Protein-tyrosine kinase Transferases Malignant tumor
- Keyword (es)
- Anticanceroso Asociación medicamentosa Cáncer del pulmón Cancerología Carcinoma no pequeňa célula bronchopulmonar Quimioterapia Erlotinib Ensayo clínico fase II Estudio comparativo Hombre Placebo Aleatorización Tratamiento Cáncer Enzima Inhibidor tyrosine kinase Inhibidor enzima Aparato respiratorio patología Bronquio patología Pulmón patología Protein-tyrosine kinase Transferases Tumor maligno
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B02 Pharmacology. Drug treatments / 002B02R Antineoplastic agents / 002B02R02 Chemotherapy
- Discipline
- Pharmacological treatments Tumours
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 24444548
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1200/JCO.2010.34.0570 
https://dx.doi.org/10.1200/JCO.2010.34.0570
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:24:\"10.1200\/JCO.2010.34.0570\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:133:\"Randomized Phase II Study of Erlotinib Plus Tivantinib Versus Erlotinib Plus Placebo in Previously Treated Non-Small-Cell Lung Cancer\";s:9:\"\u0000*\u0000jtitle\";s:28:\"Journal of clinical oncology\";s:9:\"\u0000*\u0000stitle\";s:14:\"J. clin. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2011\";s:9:\"\u0000*\u0000volume\";s:2:\"29\";s:8:\"\u0000*\u0000issue\";s:2:\"24\";s:8:\"\u0000*\u0000spage\";s:4:\"3307\";s:8:\"\u0000*\u0000epage\";s:4:\"3315\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0732-183X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"SEQUIST\";s:10:\"\u0000*\u0000aufirst\";s:7:\"Lecia V\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:14:{i:0;s:18:\"VON PAWEL, Joachim\";i:1;s:14:\"RAMLAU, Rodryg\";i:2;s:13:\"ARTHUR, Susan\";i:3;s:18:\"GORBACHEVSKY, Igor\";i:4;s:15:\"SCHWARTZ, Brian\";i:5;s:16:\"SCHILLER, Joan H\";i:6;s:16:\"GARMEY, Edward G\";i:7;s:18:\"AKERLEY, Wallace L\";i:8;s:16:\"BRUGGER, Wolfram\";i:9;s:13:\"FERRARI, Dora\";i:10;s:10:\"YINPU CHEN\";i:11;s:15:\"COSTA, Daniel B\";i:12;s:15:\"GERBER, David E\";i:13;s:13:\"ORLOV, Sergey\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:133:\"Randomized Phase II Study of Erlotinib Plus Tivantinib Versus Erlotinib Plus Placebo in Previously Treated Non-Small-Cell Lung Cancer\";s:8:\"\u0000*\u0000place\";s:14:\"Alexandria, VA\";s:6:\"\u0000*\u0000pub\";s:37:\"American Society of Clinical Oncology\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"9\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:24:\"10.1200\/JCO.2010.34.0570\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:133:\"Randomized Phase II Study of Erlotinib Plus Tivantinib Versus Erlotinib Plus Placebo in Previously Treated Non-Small-Cell Lung Cancer\";s:9:\"\u0000*\u0000jtitle\";s:28:\"Journal of clinical oncology\";s:9:\"\u0000*\u0000stitle\";s:14:\"J. clin. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2011\";s:9:\"\u0000*\u0000volume\";s:2:\"29\";s:8:\"\u0000*\u0000issue\";s:2:\"24\";s:8:\"\u0000*\u0000spage\";s:4:\"3307\";s:8:\"\u0000*\u0000epage\";s:4:\"3315\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0732-183X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"SEQUIST\";s:10:\"\u0000*\u0000aufirst\";s:7:\"Lecia V\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:14:{i:0;s:18:\"VON PAWEL, Joachim\";i:1;s:14:\"RAMLAU, Rodryg\";i:2;s:13:\"ARTHUR, Susan\";i:3;s:18:\"GORBACHEVSKY, Igor\";i:4;s:15:\"SCHWARTZ, Brian\";i:5;s:16:\"SCHILLER, Joan H\";i:6;s:16:\"GARMEY, Edward G\";i:7;s:18:\"AKERLEY, Wallace L\";i:8;s:16:\"BRUGGER, Wolfram\";i:9;s:13:\"FERRARI, Dora\";i:10;s:10:\"YINPU CHEN\";i:11;s:15:\"COSTA, Daniel B\";i:12;s:15:\"GERBER, David E\";i:13;s:13:\"ORLOV, Sergey\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:133:\"Randomized Phase II Study of Erlotinib Plus Tivantinib Versus Erlotinib Plus Placebo in Previously Treated Non-Small-Cell Lung Cancer\";s:8:\"\u0000*\u0000place\";s:14:\"Alexandria, VA\";s:6:\"\u0000*\u0000pub\";s:37:\"American Society of Clinical Oncology\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"9\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:24:\"10.1200\/JCO.2010.34.0570\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:24:\"10.1200\/JCO.2010.34.0570\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:133:\"Randomized Phase II Study of Erlotinib Plus Tivantinib Versus Erlotinib Plus Placebo in Previously Treated Non-Small-Cell Lung Cancer\";s:9:\"\u0000*\u0000jtitle\";s:28:\"Journal of clinical oncology\";s:9:\"\u0000*\u0000stitle\";s:14:\"J. clin. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2011\";s:9:\"\u0000*\u0000volume\";s:2:\"29\";s:8:\"\u0000*\u0000issue\";s:2:\"24\";s:8:\"\u0000*\u0000spage\";s:4:\"3307\";s:8:\"\u0000*\u0000epage\";s:4:\"3315\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0732-183X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"SEQUIST\";s:10:\"\u0000*\u0000aufirst\";s:7:\"Lecia V\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:14:{i:0;s:18:\"VON PAWEL, Joachim\";i:1;s:14:\"RAMLAU, Rodryg\";i:2;s:13:\"ARTHUR, Susan\";i:3;s:18:\"GORBACHEVSKY, Igor\";i:4;s:15:\"SCHWARTZ, Brian\";i:5;s:16:\"SCHILLER, Joan H\";i:6;s:16:\"GARMEY, Edward G\";i:7;s:18:\"AKERLEY, Wallace L\";i:8;s:16:\"BRUGGER, Wolfram\";i:9;s:13:\"FERRARI, Dora\";i:10;s:10:\"YINPU CHEN\";i:11;s:15:\"COSTA, Daniel B\";i:12;s:15:\"GERBER, David E\";i:13;s:13:\"ORLOV, Sergey\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:133:\"Randomized Phase II Study of Erlotinib Plus Tivantinib Versus Erlotinib Plus Placebo in Previously Treated Non-Small-Cell Lung Cancer\";s:8:\"\u0000*\u0000place\";s:14:\"Alexandria, VA\";s:6:\"\u0000*\u0000pub\";s:37:\"American Society of Clinical Oncology\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"9\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:24:\"10.1200\/JCO.2010.34.0570\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:133:\"Randomized Phase II Study of Erlotinib Plus Tivantinib Versus Erlotinib Plus Placebo in Previously Treated Non-Small-Cell Lung Cancer\";s:9:\"\u0000*\u0000jtitle\";s:28:\"Journal of clinical oncology\";s:9:\"\u0000*\u0000stitle\";s:14:\"J. clin. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2011\";s:9:\"\u0000*\u0000volume\";s:2:\"29\";s:8:\"\u0000*\u0000issue\";s:2:\"24\";s:8:\"\u0000*\u0000spage\";s:4:\"3307\";s:8:\"\u0000*\u0000epage\";s:4:\"3315\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0732-183X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"SEQUIST\";s:10:\"\u0000*\u0000aufirst\";s:7:\"Lecia V\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:14:{i:0;s:18:\"VON PAWEL, Joachim\";i:1;s:14:\"RAMLAU, Rodryg\";i:2;s:13:\"ARTHUR, Susan\";i:3;s:18:\"GORBACHEVSKY, Igor\";i:4;s:15:\"SCHWARTZ, Brian\";i:5;s:16:\"SCHILLER, Joan H\";i:6;s:16:\"GARMEY, Edward G\";i:7;s:18:\"AKERLEY, Wallace L\";i:8;s:16:\"BRUGGER, Wolfram\";i:9;s:13:\"FERRARI, Dora\";i:10;s:10:\"YINPU CHEN\";i:11;s:15:\"COSTA, Daniel B\";i:12;s:15:\"GERBER, David E\";i:13;s:13:\"ORLOV, Sergey\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:133:\"Randomized Phase II Study of Erlotinib Plus Tivantinib Versus Erlotinib Plus Placebo in Previously Treated Non-Small-Cell Lung Cancer\";s:8:\"\u0000*\u0000place\";s:14:\"Alexandria, VA\";s:6:\"\u0000*\u0000pub\";s:37:\"American Society of Clinical Oncology\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"9\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:24:\"10.1200\/JCO.2010.34.0570\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:133:\"Randomized Phase II Study of Erlotinib Plus Tivantinib Versus Erlotinib Plus Placebo in Previously Treated Non-Small-Cell Lung Cancer\";s:9:\"\u0000*\u0000jtitle\";s:28:\"Journal of clinical oncology\";s:9:\"\u0000*\u0000stitle\";s:14:\"J. clin. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2011\";s:9:\"\u0000*\u0000volume\";s:2:\"29\";s:8:\"\u0000*\u0000issue\";s:2:\"24\";s:8:\"\u0000*\u0000spage\";s:4:\"3307\";s:8:\"\u0000*\u0000epage\";s:4:\"3315\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0732-183X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"SEQUIST\";s:10:\"\u0000*\u0000aufirst\";s:7:\"Lecia V\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:14:{i:0;s:18:\"VON PAWEL, Joachim\";i:1;s:14:\"RAMLAU, Rodryg\";i:2;s:13:\"ARTHUR, Susan\";i:3;s:18:\"GORBACHEVSKY, Igor\";i:4;s:15:\"SCHWARTZ, Brian\";i:5;s:16:\"SCHILLER, Joan H\";i:6;s:16:\"GARMEY, Edward G\";i:7;s:18:\"AKERLEY, Wallace L\";i:8;s:16:\"BRUGGER, Wolfram\";i:9;s:13:\"FERRARI, Dora\";i:10;s:10:\"YINPU CHEN\";i:11;s:15:\"COSTA, Daniel B\";i:12;s:15:\"GERBER, David E\";i:13;s:13:\"ORLOV, Sergey\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:133:\"Randomized Phase II Study of Erlotinib Plus Tivantinib Versus Erlotinib Plus Placebo in Previously Treated Non-Small-Cell Lung Cancer\";s:8:\"\u0000*\u0000place\";s:14:\"Alexandria, VA\";s:6:\"\u0000*\u0000pub\";s:37:\"American Society of Clinical Oncology\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"9\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
